What Surolan Treats: Main Uses and Benefits

This medication is generally used to help with conditions characterized by periods of heightened symptoms in dogs and cats, particularly those involving the external ear canal or localized skin areas. It is utilized for conditions presenting with systemic or localized discomfort, particularly otic infections and dermatitis associated with microbial activity.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns. It is commonly used to help with conditions presenting with infectious and inflammatory manifestations, including otitis externa, multi-factorial skin afflictions, and secondary infections following ear mite infestation.

“It is commonly used when short-term symptomatic assistance is needed for concurrent microbial and inflammatory distress.”

The medication is relevant for easing symptoms that become more disruptive during flare-ups, including pronounced itching (pruritus), localized pain, and related swelling. This domain is relevant when supportive symptom management is appropriate, as it contributes to easing the overall symptom load. This supportive relief may assist with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Relief for Acute Discomfort

Symptom Focus	Context of Use	Patient Benefit
Intense Itching (Pruritus)	Symptom escalation in chronic disease	Helps maintain functional stability
Localized Pain & Swelling	Acute inflammatory episodes	Provides supportive relief when needed
Microbial Overgrowth	Multi-factorial infection scenarios	Assists with managing the pathogenic burden

Regulatory References

1. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/862

The eligibility for using Surolan is determined by official regulatory documents, strictly limiting its use to Dogs and Cats for topical administration only.

Contraindicated Populations

Use is contraindicated in animals with known hypersensitivity to Miconazole Nitrate, Polymyxin B Sulfate, Prednisolone Acetate, or any of the product's excipients. Furthermore, the otic suspension must not be used in the ear if an animal has a confirmed or suspected non-intact tympanic membrane (perforated eardrum), which is an absolute anatomical contraindication.

Restricted and Non-Recommended Use

Eligibility is officially restricted for animals in reproductive states. Use is not recommended in pregnant, lactating, or breeding animals, as regulatory data on safety in these populations have not been established. Conditional consideration is required for animals with pre-existing conditions like Hyperadrenocorticism (Cushing's Disease) due to the corticosteroid component. The product is also restricted to infections caused only by susceptible strains of yeast and bacteria.

Interactions with other medicines and products

Regulatory documentation defines a specific restriction regarding the co-administration of Surolan with other substances. This veterinary product's interaction profile is primarily governed by a prohibited combination and the risk associated with systemic exposure to one of its components during prolonged use.

Official Interaction Statements

Category	Regulatory Restriction/Statement
Prohibited Combination	Co-administration with medicinal products explicitly known to induce ototoxicity (potential for harm to the ear) is formally restricted and must be avoided.
Pharmacodynamic Interaction	A synergistic effect between the active components, Miconazole Nitrate and Polymyxin B Sulfate, against specific microbial pathogens is documented in in vitro data.
Systemic Exposure Risk	The potential for the topical corticosteroid component (Prednisolone Acetate) to cause systemic effects, such as adrenocortical suppression and iatrogenic hypoadrenocorticism, is noted in regulatory warnings when the product is used over an extended duration. This is not a drug-drug interaction but a use-context constraint.

No explicit pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transporters, are universally documented in the official prescribing information for this topical route of administration. Furthermore, official labeling does not include mandatory timing separation requirements or specific documented interactions with food, alcohol, or herbal products.

The action of the combination product stems from three distinct and synergistic pharmacodynamic domains that simultaneously disrupt microbial function and modulate host inflammatory signaling pathways.

Disrupting Microbial Cell Membrane Integrity

This mechanistic domain involves the two anti-infective components, Miconazole Nitrate and Polymyxin B, which target specific structures required for microbial cell integrity and metabolic function. Miconazole inhibits a key fungal enzyme, 14alpha-demethylase, which blocks the synthesis of ergosterol and causes significant membrane stress and destabilization. Simultaneously, Polymyxin B utilizes an electrostatic mechanism to bind and destabilize the outer Lipopolysaccharide (LPS) membrane of susceptible Gram-negative bacteria, leading to structural permeabilization and loss of cytoplasmic contents.

Genomic Suppression of the Inflammatory Cascade ️

The third component, Prednisolone Acetate, engages a distinct host defense mechanism by acting as an agonist on the intracellular Glucocorticoid Receptor (GR). This binding modulates gene expression to upregulate anti-inflammatory proteins, which in turn inhibit the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug interrupts the release of arachidonic acid, a critical precursor, thereby preventing the synthesis of local inflammatory mediators like prostaglandins and leukotrienes. This upstream blockade of mediator synthesis leads to the modulation of physiological signaling pathways in the local environment, which includes the chemical pathways associated with afferent neural activity.

The use of Surolan Otic Suspension is administered by or on the order of a licensed veterinarian. This medication is for topical use only, applied to the affected ear(s) or skin area. It is not for human or oral use in animals.

Official Administration Steps

Before initiating treatment, it is mandatory to confirm the integrity of the eardrum and thoroughly clean and dry the external ear canal.

1. Preparation: The bottle must be shaken vigorously before each use to ensure the product is fully resuspended.
2. Dosing (Otic Use in Dogs): Instill 5 drops of the suspension into the ear canal.
3. Frequency and Duration (Dogs): Apply the dose twice daily (BID) for a total of 7 consecutive days.
4. Distribution: After instillation, gently but thoroughly massage the ear to ensure the medication is properly distributed throughout the ear canal.

Special Dosing Considerations

• Cutaneous Use: For skin infections, apply a few drops (depending on the size of the lesion) to the clean, affected area twice daily and rub in well. Hair around or covering the lesions should be clipped.
• Missed Dose: If a dose is missed, administer it as soon as it is remembered. If it is close to the time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Do not double the dose to compensate.

The safe use of this product has not been evaluated in breeding dogs, pregnant dogs, or lactating bitches.

Research evidence / Overview of studies for Surolan

Evidence for use in Canine Otitis Externa

Research exploring the use of this combination product in dogs primarily consists of regulatory field trials applied in research contexts involving fluctuating or unstable symptoms of external ear inflammation. These short-term studies were structured to compare the product's use against other active topical treatments. They included client-owned dogs diagnosed with otitis externa associated with certain susceptible bacteria and yeast.

Research examined clinical sign scores, such as pain, redness, and exudate (discharge), which are outcomes related to physical discomfort and inflammatory states. Findings describe patterns observed in the studies where the measured changes in clinical signs and microbial status were compared to those observed with the active control product. While these regulatory field trials provide required context on how the product compared to other active treatments, follow-up durations were limited.

Evidence for use in Feline Otic and Dermal Afflictions

The research base for cats is more limited than that for dogs, but research has examined its use in specific feline conditions, including Otocariasis (ear mite) infestation. For ear mite-associated symptoms, research examined outcomes related to physical discomfort, such as itching and the severity of exudate. Studies monitored the absence of mites following the defined treatment period.

In these comparative trials, findings indicate patterns related to the resolution of the mite infestation and the corresponding changes in associated inflammatory symptoms. This evidence contributes to understanding symptom patterns over the short term. However, since the product does not contain a dedicated anti-parasitic agent, research is ongoing to fully understand the factors related to the observed outcomes involving mite clearance.

Research Gaps and Remaining Uncertainties

Long-term effects are not fully established in the publicly available regulatory evidence. Data for outcomes reflecting long-term stability or maintenance beyond the intermediate follow-up periods remain insufficient. The main regulatory evidence focuses on a broad population of client-owned dogs and cats with confirmed clinical infections, meaning results apply only to the populations studied in the submitted field trials. Further research is needed to better understand the short-term study findings and long-term recurrence rates across diverse populations.

Key Studies & References NADA 141-298 Original Approval: Surolan Otic Suspension - Freedom of Information Summary

Common questions about Surolan (FAQ)

Q: Is Surolan a steroid medication?

A: Official product information classifies Surolan as a triple-action combination product containing a corticosteroid and two anti-infectives. It includes Prednisolone Acetate, which is an active corticosteroid component intended to modulate inflammation.

Q: Why is Surolan used for multiple different conditions?

A: Regulatory documents indicate that the product is formulated to address both the microbial causes and the symptoms of infection. It is specifically indicated for topical treatment of otic (ear) and skin infections when the causative pathogens are susceptible to its antifungal and antibacterial components, alongside treating the accompanying inflammation.

Q: Can Surolan be used long-term?

A: Official documentation notes that using the topical corticosteroid component over an extended duration is associated with the potential for systemic effects. These include the risk of adrenocortical suppression, which is a regulatory concern tied to prolonged use.

Q: Does Surolan treat infections or just inflammation?

A: The formulation is designed to provide concurrent antibacterial, antifungal, and anti-inflammatory activity. Therefore, official documents confirm that it targets both microbial causes of infection and the associated inflammation.

Q: What happens if you miss an application of Surolan?

A: Official documentation describes a protocol for a missed application, stating the dose is typically administered as soon as it is remembered. If it is close to the next scheduled time, the recommendation described in the protocol is to skip the missed dose and resume the regular schedule.

Q: What are the signs that Surolan is starting to have an effect?

A: Studies used for regulatory approval examined clinical sign scores related to physical discomfort and inflammatory states. The examined outcomes in research included changes in clinical signs such as pain, redness, and the level of exudate (discharge), which are related to physical discomfort and inflammation.

Q: Are there any food or diet restrictions while using Surolan?

A: Regulatory documentation for this topical product does not include mandatory timing separation requirements or specific documented interactions with food, alcohol, or herbal products.

Q: Has there been research on Surolan's effectiveness?

A: Yes, regulatory field trials are a required part of the approval process. These studies have been conducted to demonstrate that the product is safe and effective for its indicated uses when applied according to the label information.

Q: Is Surolan available over-the-counter?

A: According to official regulatory classifications, Surolan is a prescription-only medicine (POM). Its use is restricted to being administered by or on the order of a licensed veterinarian.

Q: Can Surolan be used on parts of the body other than the ears?

A: Official indications for the product include treatment for both otic (ear) infections and certain dermal (skin) infections caused by susceptible pathogens. It is applied topically to the affected area.

Q: How long does a typical course of Surolan application last?

A: Official dosage and administration information often specifies a duration of 7 consecutive days for canine otitis externa. A veterinary assessment is typically recommended following this period to determine if treatment should be extended.

Q: Are there any specific safety warnings about Surolan?

A: Specific safety warnings include restrictions against using the product in animals with a perforated eardrum. Cautions are also noted regarding the risk of systemic effects from the corticosteroid component if the product is used long-term.

Q: Does Surolan contain an ingredient for pain relief?

A: The active ingredients are an antibiotic, an antifungal, and a corticosteroid. While no dedicated pain reliever is listed, the anti-inflammatory activity of the corticosteroid component (Prednisolone Acetate) is intended to mitigate the pain and intense itching associated with severe topical inflammation.

Q: Is it possible to be allergic to an ingredient in Surolan?

A: Yes, the product is formally contraindicated in animals with a known or suspected hypersensitivity (allergic reaction) to any of the active substances (Miconazole Nitrate, Polymyxin B, Prednisolone Acetate) or the non-active ingredients.

Q: What should be done if Surolan is accidentally swallowed?

A: Official documentation notes that in cases of accidental ingestion (e.g., by licking), no toxic effects were observed in studies. However, the product is not for human use, and official information notes that contact with a physician is appropriate if human exposure occurs.

Q: Does Surolan need to be refrigerated?

A: Official regulatory information requires that the product be stored at or below 25 C (77 F). This guidance indicates that standard room temperature storage is appropriate, and refrigeration is not required.

Q: How is the safety of Surolan monitored after it is approved?

A: Like all approved medicines, the safety of Surolan is subject to continuous pharmacovigilance (post-authorisation safety monitoring). This system requires the reporting of observed adverse events and ongoing safety assessment by regulatory bodies.

Q: What happens if Surolan is used past its expiration date?

A: Official documents strictly state that the product must not be used after the expiry date printed on the packaging. The safety, quality, and guaranteed effectiveness of the medicine are only assured up to that date.

Q: Are there different strengths or formulations of Surolan available?

A: The official label defines a single standard strength containing a specific concentration of Miconazole Nitrate, Polymyxin B Sulfate, and Prednisolone Acetate. Regulatory documents generally refer to this one concentration.

Q: Why do official documents list several precautions for Surolan?

A: Precautions are included in the official labeling to inform users and veterinarians about specific, known risks associated with its active ingredients. These include the potential for ototoxicity (ear damage) and the risks of systemic effects from the corticosteroid component.

Q: Does the active corticosteroid in Surolan absorb into the body?

A: Regulatory documents note the potential for the topical corticosteroid component to cause systemic effects. Studies have shown that the compound can exhibit negligible systemic absorption through intact skin or mucous membranes when used as directed.

Q: What is the in-use stability period for Surolan once the bottle is opened?

A: The official regulatory documentation defines a strict in-use stability period, or shelf life after first opening the immediate packaging, of three months.

Q: Are there common side effects people notice with Surolan?

A: The official label classifies the most notable adverse events, such as deafness/impaired hearing and hypersensitivity reactions, as Very Rare (occurring in less than 1 in 10,000 animals treated). Common or frequent reactions are not typically classified with the same level of detail in regulatory documents.

Q: Does Surolan affect hearing or skin pigmentation?

A: The safety profile includes the risk of deafness or impaired hearing as a Very Rare adverse reaction. Official notes also indicate that prolonged use of topical steroids can potentially cause changes in skin appearance, such as discoloration.

Q: What are the reported major adverse events associated with Surolan?

A: Key safety concerns noted in official documentation include the potential for deafness or impaired hearing. Another major concern is the risk of adrenocortical suppression (an endocrine disorder) when the corticosteroid component is used over an extended duration.

Q: Can children or elderly people use Surolan?

A: Official safety data has not been evaluated for young animals. Regulatory notes specifically point out that impaired hearing has been observed mainly in elderly dogs.

Q: Is it safe to use Surolan if the skin is broken or damaged?

A: The product is contraindicated in animals with a perforated eardrum. While studies show minimal absorption through intact or damaged skin, due to the severe ear contraindication, use on any broken or damaged skin requires professional guidance and should be discussed with a veterinarian.

Q: Can Surolan be used with cleaning or rinsing solutions?

A: Official administration steps require the affected ear to be thoroughly cleaned and dried before the initiation of treatment. The decision to use cleaning solutions during the course of treatment requires professional assessment.

Q: What is the difference between Surolan and preparations that contain only one active ingredient?

A: Surolan is defined as a triple-action combination product. This means it is designed to simultaneously provide antibacterial, antifungal, and anti-inflammatory activity, which differs from single-ingredient preparations that focus only on one type of effect.

How to Store and Dispose of Surolan

Official regulatory information requires that Surolan be stored at or below 25 C (77 F). The product must be kept in its original container and the outer carton to protect the medicine.

Before each use, the bottle must be shaken vigorously to ensure the suspension is fully prepared. Once the bottle is opened, the medicine has a strict in-use stability period of three months.

Safety and Disposal

For safety, the product must be stored out of the sight and reach of children. Unused medicine or waste material must not be disposed of via wastewater and must be discarded in accordance with local requirements.